<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">ksma</journal-id><journal-title-group><journal-title xml:lang="ru">Кубанский научный медицинский вестник</journal-title><trans-title-group xml:lang="en"><trans-title>Kuban Scientific Medical Bulletin</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1608-6228</issn><issn pub-type="epub">2541-9544</issn><publisher><publisher-name>Kuban State Medical University</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.25207/1608-6228-2020-27-6-123-135</article-id><article-id custom-type="elpub" pub-id-type="custom">ksma-2239</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОБЗОРЫ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>REVIEW</subject></subj-group></article-categories><title-group><article-title>Предикторы возникновения артериальной гипертензии у детей (обзор)</article-title><trans-title-group xml:lang="en"><trans-title>Predictors of arterial hypertension in children (A Review)</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9653-6365</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бурлуцкая</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Burlutskaya</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Бурлуцкая Алла Владимировна — доктор медицинских наук, доцент, заведующая кафедрой педиатрии № 2</p><p>ул. им. Митрофана Седина, д. 4, г. Краснодар, 350063</p></bio><bio xml:lang="en"><p>Alla V. Burlutskaya — Dr. Sci. (Med.), Assoc. Prof., Head of the Chair of Paediatrics No. 2</p><p>Mitrofanа Sedina str., 4, Krasnodar, 350063</p></bio><email xlink:type="simple">gped2@lenta.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1097-0698</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Коробкина</surname><given-names>О. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Korobkina</surname><given-names>O. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Коробкина Ольга Геннадьевна — ординатор второго года обучения кафедры педиатрии № 2</p><p>ул. им. Митрофана Седина, д. 4, г. Краснодар, 350063тел.: +7 (918) 988-71-98 </p></bio><bio xml:lang="en"><p>Olga G. Korobkina — Clinical Resident (2nd year), Chair of Paediatrics No. 2</p><p>Mitrofanа Sedina str., 4, Krasnodar, 350063tel.: +7 (918) 988-71-98 </p></bio><email xlink:type="simple">olga_k_17@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Федеральное государственное бюджетное образовательное учреждение высшего образования «Кубанский государственный медицинский университет» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Kuban State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="epub"><day>02</day><month>11</month><year>2020</year></pub-date><volume>27</volume><issue>6</issue><fpage>123</fpage><lpage>135</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Бурлуцкая А.В., Коробкина О.Г., 2020</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="ru">Бурлуцкая А.В., Коробкина О.Г.</copyright-holder><copyright-holder xml:lang="en">Burlutskaya A.V., Korobkina O.G.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://ksma.elpub.ru/jour/article/view/2239">https://ksma.elpub.ru/jour/article/view/2239</self-uri><abstract><sec><title>Введение</title><p>Введение. Актуальность проблемы артериальной гипертензии не вызывает сомнений. Известно, что «корни» повышения артериального давления уходят глубоко в детство. Сегодня артериальная гипертензия у детей и подростков рассматривается как довольно часто встречающаяся патология. Без сомнений, профилактика и лечение артериальной гипертензии эффективнее на ее ранней стадии. Именно поэтому важно изучать новые звенья патогенеза данного заболевания и возможные в этой связи методы коррекции.</p><p>Цель обзора — осветить современные теории влияния микробиоты на риск возникновения артериальной гипертензии у детей.</p></sec><sec><title>Методы</title><p>Методы. Проведен анализ российской и зарубежной литературы в базах Elibrary, Web of Science, PubMed. Были использованы ключевые слова: «gut microbiota», «arterial hypertension», «children», «chronic systemic inﬂammation», «probiotics», «артериальная гипертензия», «дети», «хроническое системное воспаление», «пробиотики». Все научные работы, включенные в обзор, были опубликованы в последние 7 лет. Методы исследования, использованные в процессе анализа: контент-анализ, описательноаналитический.</p></sec><sec><title>Результаты</title><p>Результаты. Известно, что артериальная гипертензия по-прежнему остается очень важной экономической и медико-социальной проблемой, являясь главной причиной заболеваний мозга и ишемической болезни сердца. Установлено, что истоки повышения артериального давления находятся в детском и подростковом возрасте, в период становления процессов регуляции. В настоящее время накоплены многочисленные данные о вовлечении в патогенез артериальной гипертензии микроорганизмов, населяющих человека. Микробиота в детском возрасте более нестабильна, чем у взрослых. Предполагают, что соотношение между классами микроорганизмов имеет большое значение в сохранении здоровья, а дисбаланс кишечной микробиоты может привести к существенным последствиям. Получены сведения о влиянии последней на развитие хронического системного воспаления, липидный обмен, формирование и прогрессирование атеросклероза. Известно положительное влияние на течение артериальной гипертензии и уровень холестерина определенных штаммов бактерий. Выяснены некоторые механизмы, посредством которых микробиота может воздействовать на артериальное давление. Разрабатываются и совершенствуются методы коррекции нарушенного баланса микроорганизмов: диета, применение антибиотиков, пребиотиков, пробиотиков и трансплантация фекальной микробиоты.</p></sec><sec><title>Заключение</title><p>Заключение. Полученные результаты дают надежду на разработку и внедрение в клиническую практику новых методов лечения артериальной гипертензии, применение которых на ранних этапах, а именно в детском возрасте, позволит в дальнейшем избежать некорригируемых осложнений.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Background</title><p>Background. Arterial hypertension poses a relevant problem and roots in early childhood. Today, arterial hypertension in children and adolescents is considered rather common and should be controlled and prevented as early as possible, which warrants further research into its pathogenesis and effective correction.</p></sec><sec><title>Objectives</title><p>Objectives. To generalize current knowledge of microbiota in the development of arterial hypertension in children.</p></sec><sec><title>Methods</title><p>Methods. National and foreign published sources were surveyed in the eLibrary, Web of Science and PubMed databases. Keyword queries were: gut microbiota, arterial hypertension [артериальная гипертензия], children [дети], chronic systemic inﬂammation [хроническое системное воспаление], probiotics [пробиотики]. All sources have a publication depth of 7 years. The study used content analysis and descriptive analytics.</p></sec><sec><title>Results</title><p>Results. Arterial hypertension remains a problem of high economic, medical and social importance as a major cause of brain disorders and coronary heart disease. Hypertension is shown to emerge early in childhood and adolescence during the regulatory network formation. Manifold evidence is accumulated on the involvement of human microbiota in pathogenesis of arterial hypertension. Infant microbiota is more unstable than in adults. Its taxonomic proﬁle is viewed important for sustaining health, with imbalances in intestinal microbiota potentially entailing serious consequences. The impact of microbiota on chronic systemic inﬂammation, lipid metabolism, development and progression of atherosclerosis has been reported. Certain bacterial strains are known to exert benign effect on arterial hypertension and blood cholesterol. Selected mechanisms of the microbiota-mediated regulation of blood pressure have been identiﬁed. Improved methods for microbial community correction are being developed and include diet, antibiotic, prebiotic and probiotic regimens, faecal microbiota transplant.</p></sec><sec><title>Conclusion</title><p>Conclusion. Current achievements promise the emergence of novel approaches for arterial hypertension control early in childhood to avoid incorrigible adult complications.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>артериальная гипертензия</kwd><kwd>дети</kwd><kwd>микробиота</kwd></kwd-group><kwd-group xml:lang="en"><kwd>arterial hypertension</kwd><kwd>children</kwd><kwd>microbiota</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Агапитов Л.И., Черепнина И.В. Диагностика и лечение артериальной гипертензии у детей и подростков в свете новых клинических рекомендаций Американской академии педиатрии. Российский вестник перинатологии и педиатрии. 2019; 64(4): 114–127. DOI: 10.21508/1027-4065-2019-644-114-127</mixed-citation><mixed-citation xml:lang="en">Agapitov L.I., Cherepnina I.V. Diagnostics and treatment of arterial hypertension in children and adolescents, overview of new clinical guidelines of the American Academy of Pediatrics. Russian Bulletin of Perinatology and Pediatrics. 2019; 64(4): 114–127 (In Russ., English abstract). DOI: 10.21508/1027-4065-2019-64-4-114-127</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Skinner A.C., Perrin E.M., Moss L.A., Skelton J.A. Cardiometabolic Risks and Severity of Obesity in Children and Young Adults. N. Engl. J. Med. 2015; 373(14): 1307–1317. DOI: 10.1056/NEJMoa1502821</mixed-citation><mixed-citation xml:lang="en">Skinner A.C., Perrin E.M., Moss L.A., Skelton J.A. Cardiometabolic Risks and Severity of Obesity in Children and Young Adults. N. Engl. J. Med. 2015; 373(14): 1307–1317. DOI: 10.1056/NEJMoa1502821</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Николаева И.В., Царегородцев А.Д., Шайхиева Г.С. Формирование кишечной микробиоты ребенка и факторы, влияющие на этот процесс. Российский вестник перинатологии и педиатрии. 2018; 63(3): 13–18. DOI: 10.21508/1027-40652018-63-3-13-18</mixed-citation><mixed-citation xml:lang="en">Nikolaeva I.V., Tsaregorodtsev A.D., Shaikhieva G.S. Formation of the intestinal microbiota of children and the factors that inﬂuence this process. Russian Bulletin of Perinatology and Pediatrics. 2018; 63(3): 1318 (In Russ., English abstract). DOI: 10.21508/10274065-2018-63-3-13-18</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Харитонова Л.А., Григорьев К.И., Борзакова С.Н. Микробиота человека: как новая научная парадигма меняет медицинскую практику. Экспериментальная и клиническая гастроэнтерология. 2019; 161(1): 55–63. DOI: 10.31146/1682-8658-ecg161-1-55-63</mixed-citation><mixed-citation xml:lang="en">Kharitonova L.A., Grigoriev K.I., Borzakova S.N. Human microbiote: how a new scientiﬁ c paradigm changes medical practice. Experimental and Clinical Gastroenterology. 2019; 161(1): 55–63 (In Russ., English abstract). DOI: 10.31146/1682-8658-ecg-161-1-55-63</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Макарова С.Г., Намазова-Баранова Л.С., Ерешко О.А., Ясаков Д.С., Садчиков П.Е. Кишечная микробиота и аллергия. Про- и пребиотики в профилактике и лечении аллергических заболеваний. Педиатрическая фармакология. 2019; 16(1): 7–18. DOI: 10.15690/pf.v16i1.1999</mixed-citation><mixed-citation xml:lang="en">Makarova S.G., Namazova-Baranova L.S., Ereshko O.A., Yasakov D.S., Sadchikov P.E. Intestinal microbiota and allergy. Probiotics and prebiotics in prevention and treatment of allergic diseases. Pediatric Pharmacology. 2019; 16(1): 7–18 (In Russ., English abstract). DOI: 10.15690/pf.v16i1.1999</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Хохлачева Н.А., Глазырина Н.Н., Лукашевич А.П., Вахрушев Я.М., Косарева Т.С. Роль микрофлоры кишечника в развитии желчнокаменной болезни (обзор литературы). Архивъ внутренней медицины. 2020; 10(1): 31–37. DOI: 10.20514/2226-67042020-10-1-31-37</mixed-citation><mixed-citation xml:lang="en">Hohlacheva N.A., Glazyrina N.N., Lukashevich A.P., Vahrushev J.M., Kosareva T.S. The role of intestinal microﬂora in the development of cholelithiasis (literature review). The Russian Archives of Internal Medicine. 2020; 10(1): 31–37 (In Russ., English abstract). DOI: 10.20514/2226-6704-2020-10-1-31-37</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Хавкин А.И., Комарова О.Н. Продукты метаболизма кишечной микрофлоры: возможна ли избирательная коррекция? Вопросы современной педиатрии. 2015; 14(2): 212–218. DOI: 10.15690/vsp.v14i2.1289</mixed-citation><mixed-citation xml:lang="en">Khavkin A.I., Komarova O.N. Products of metabolism of the intestinal microﬂora: can we use the selective correction? Current Pediatrics. 2015; 14(2): 212–218 (In Russ., English abstract). DOI: 10.15690/vsp.v14i2.1289</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Sampson T.R., Mazmanian S.K. Control of brain development, function, and behavior by the microbiome. Cell Host. Microbe. 2015; 17(5): 565–576. DOI: 10.1016/j.chom.2015.04.011</mixed-citation><mixed-citation xml:lang="en">Sampson T.R., Mazmanian S.K. Control of brain development, function, and behavior by the microbiome. Cell Host. Microbe. 2015; 17(5): 565–576. DOI: 10.1016/j.chom.2015.04.011</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Кардымон О.Л., Кудрявцева А.В. Молекулярно-генетические методы для исследования микробиома кишечника. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2016; 26(4): 4–13. DOI: 10.22416/1382-4376-2016-26-4-4-13</mixed-citation><mixed-citation xml:lang="en">Kardymon O.L., Kudryavtseva A.V. Molecular genetic methods for intestinal microbiome investigation. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2016; 26(4): 4–13 (In Russ., English abstract). DOI: 10.22416/1382-4376-2016-26-4-4-13</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Макарова С.Г., Броева М.И. Влияние различных факторов на ранние этапы формирования кишечной микробиоты. Педиатрическая фармакология. 2016; 13(3): 270–282. DOI: 10.15690/pf.v13i3.1577</mixed-citation><mixed-citation xml:lang="en">Makarova S.G., Broeva M.I. Different Factors Inﬂuencing Early Stages of Intestine Microbiota Formation. Pediatric Pharmacology. 2016; 13(3): 270–282 (In Russ., English abstract). DOI: 10.15690/pf.v13i3.1577</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Payne M.S., Bayatibojakhi S. Exploring preterm birth as a polymicrobial disease: an overview of the uterine microbiome. Front. Immunol. 2014; 5: 595. DOI: 10.3389/ﬁmmu.2014.00595</mixed-citation><mixed-citation xml:lang="en">Payne M.S., Bayatibojakhi S. Exploring preterm birth as a polymicrobial disease: an overview of the uterine microbiome. Front. Immunol. 2014; 5: 595. DOI: 10.3389/ﬁmmu.2014.00595</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Hansen R., Scott K.P., Khan S., Martin J.C., Berry S.H., Stevenson M., et al. First-Pass meconium samples from healthy term vaginally-delivered neonates: an analysis of the microbiota. PLoS One. 2015; 10(7): e0133320. DOI: 10.1371/journal.pone.0133320</mixed-citation><mixed-citation xml:lang="en">Hansen R., Scott K.P., Khan S., Martin J.C., Berry S.H., Stevenson M., et al. First-Pass meconium samples from healthy term vaginally-delivered neonates: an analysis of the microbiota. PLoS One. 2015; 10(7): e0133320. DOI: 10.1371/journal.pone.0133320</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Hesla H.M., Stenius F., Jäderlund L., Nelson R., Engstrand L., Alm J., Dicksved J. Impact of lifestyle on the gut microbiota of healthy infants and their mothers the ALADDIN birth cohort. FEMS Microbiol. Ecol. 2014; 90(3): 791–801. DOI: 10.1111/1574-6941.12434</mixed-citation><mixed-citation xml:lang="en">Hesla H.M., Stenius F., Jäderlund L., Nelson R., Engstrand L., Alm J., Dicksved J. Impact of lifestyle on the gut microbiota of healthy infants and their mothers the ALADDIN birth cohort. FEMS Microbiol. Ecol. 2014; 90(3): 791–801. DOI: 10.1111/1574-6941.12434</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Lee E., Kim B.J., Kang M.J., Choi K.Y., Cho H.J., Kim Y., et al. Dynamics of gut microbiota according to the delivery mode in healthy korean infants. Allergy Asthma Immunol. Res. 2016; 8(5): 471–477. DOI: 10.4168/aair.2016.8.5.471</mixed-citation><mixed-citation xml:lang="en">Lee E., Kim B.J., Kang M.J., Choi K.Y., Cho H.J., Kim Y., et al. Dynamics of gut microbiota according to the delivery mode in healthy korean infants. Allergy Asthma Immunol. Res. 2016; 8(5): 471–477. DOI: 10.4168/aair.2016.8.5.471</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Rutayisire E., Huang K., Liu Y., Tao F. The mode of delivery affects the diversity and colonization pattern of the gut microbiota during the ﬁrst year of infants’ life: a systematic review. BMC Gastroenterol. 2016; 16(1): 86. DOI: 10.1186/s12876-016-0498-0</mixed-citation><mixed-citation xml:lang="en">Rutayisire E., Huang K., Liu Y., Tao F. The mode of delivery affects the diversity and colonization pattern of the gut microbiota during the ﬁrst year of infants’ life: a systematic review. BMC Gastroenterol. 2016; 16(1): 86. DOI: 10.1186/s12876-016-0498-0</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Айтбаев К.А., Муркамилов И.Т. Кишечная микробиота: роль в патогенезе артериальной гипертензии. Клиническая медицина. 2017; 95(2): 123–126. DOI: 10.18821/0023-2149-2017-95-2-123-126</mixed-citation><mixed-citation xml:lang="en">Aitbaev K.A., Murkamilov I.E. Intestinal microbiota: its role in pathogenesis of arterial hypertension. Klinicheskaya Meditsina. 2017; 95(2): 123–126 (In Russ., English abstract). DOI: 10.18821/0023-2149-201795-2-123-126</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Каштанова Д.А., Ткачева О.Н., Бойцов С.А. Микробиота кишечника и факторы кардиоваскулярного риска. Часть IV. Артериальная гипертония, курение и микробиота кишечника. Кардиоваскулярная терапия и профилактика. 2016; 15(1): 69–72. DOI: 10.15829/1728-8800-2016-1-69-72</mixed-citation><mixed-citation xml:lang="en">Kashtanova D.A., Tkacheva O.N., Boytsov S.A. Gut microbiota and cardiovascular risk factors. Part IV. Arterial hypertension, smoking and the gut microbiota. Cardiovascular Therapy and Prevention. 2016; 15(1): 69–72 (In Russ., English abstract). DOI: 10.15829/1728-8800-2016-1-69-72</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Andrade-Oliveira V., Amano M.T., Correa-Costa M., Castoldi A., Felizardo R.J., Almeida D.C., et al. Gut Bacteria products prevent AKI induced by ischemia-reperfusion. J. Am. Soc. Nephrol. 2015; 26(8): 1877–1888. DOI: 10.1681/ASN.2014030288</mixed-citation><mixed-citation xml:lang="en">Andrade-Oliveira V., Amano M.T., Correa-Costa M., Castoldi A., Felizardo R.J., Almeida D.C., et al. Gut Bacteria products prevent AKI induced by ischemia-reperfusion. J. Am. Soc. Nephrol. 2015; 26(8): 1877–1888. DOI: 10.1681/ASN.2014030288</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Yang T., Santisteban M.M., Rodriguez V., Li E., Ahmari N., Carvajal J.M., et al. Gut dysbiosis is linked to hypertension. Hypertension. 2015; 65(6): 13311340. DOI: 10.1161/HYPERTENSIONAHA.115.05315</mixed-citation><mixed-citation xml:lang="en">Yang T., Santisteban M.M., Rodriguez V., Li E., Ahmari N., Carvajal J.M., et al. Gut dysbiosis is linked to hypertension. Hypertension. 2015; 65(6): 1331–1340. DOI: 10.1161/HYPERTENSIONAHA.115.05315</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Драпкина О.М., Широбоких О.Е. Роль кишечной микробиоты в патогенезе сердечно-сосудистых заболеваний и метаболического синдрома. Рациональная Фармакотерапия в Кардиологии. 2018; 14(4): 567–574. DOI: 10.20996/1819-6446-2018-144-567-574</mixed-citation><mixed-citation xml:lang="en">Drapkina O.M., Shirobokikh O.E. Role of gut microbiota in the pathogenesis of cardiovascular diseases and metabolic syndrome. Rational Pharmacotherapy in Cardiology. 2018; 14(4): 567–574 (In Russ., English abstract). DOI: 10.20996/1819-6446-2018-14-4-567-574</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Li J., Zhao F., Wang Y., Chen J., Tao J., Tian G., et al. Gut microbiota dysbiosis contributes to the development of hypertension. Microbiome. 2017; 5(1): 14. DOI: 10.1186/s40168-016-0222-x</mixed-citation><mixed-citation xml:lang="en">Li J., Zhao F., Wang Y., Chen J., Tao J., Tian G., et al. Gut microbiota dysbiosis contributes to the development of hypertension. Microbiome. 2017; 5(1): 14. DOI: 10.1186/s40168-016-0222-x</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Collins H.L., Drazul-Schrader D., Sulpizio A.C., Koster P.D., Williamson Y., Adelman S.J., et al. LCarnitine intake and high trimethylamine N-oxide plasma levels correlate with low aortic lesions in ApoE(–/–) transgenic mice expressing CETP. Atherosclerosis. 2016; 244: 29–37. DOI: 10.1016/j.atherosclerosis.2015.10.108</mixed-citation><mixed-citation xml:lang="en">Collins H.L., Drazul-Schrader D., Sulpizio A.C., Koster P.D., Williamson Y., Adelman S.J., et al. L-Carnitine intake and high trimethylamine N-oxide plasma levels correlate with low aortic lesions in ApoE(–/–) transgenic mice expressing CETP. Atherosclerosis. 2016; 244: 29–37. DOI: 10.1016/j.atherosclerosis.2015.10.108</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Mueller D.M., Allenspach M., Othman A., Saely C.H., Muendlein A., Vonbank A., et al. Plasma levels of trimethylamine-N-oxide are confounded by impaired kidney function and poor metabolic control. Atherosclerosis. 2015; 243(2): 638–644. DOI: 10.1016/j.atherosclerosis.2015.10.091</mixed-citation><mixed-citation xml:lang="en">Mueller D.M., Allenspach M., Othman A., Saely C.H., Muendlein A., Vonbank A., et al. Plasma levels of trimethylamine-N-oxide are confounded by impaired kidney function and poor metabolic control. Atherosclerosis. 2015; 243(2): 638–644. DOI: 10.1016/j.atherosclerosis.2015.10.091</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Zhu W., Gregory J.C., Org E., Buffa J.A., Gupta N., Wang Z., et al. Gut Microbial metabolite TMAO enhances platelet hyperreactivity and thrombosis risk. Cell. 2016; 165(1): 111–124. DOI: 10.1016/j.cell.2016.02.011</mixed-citation><mixed-citation xml:lang="en">Zhu W., Gregory J.C., Org E., Buffa J.A., Gupta N., Wang Z., et al. Gut Microbial metabolite TMAO enhances platelet hyperreactivity and thrombosis risk. Cell. 2016; 165(1): 111–124. DOI: 10.1016/j.cell.2016.02.011</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Al-Obaide M.A.I., Singh R., Datta P., RewersFelkins K.A., Salguero M.V., Al-Obaidi I., et al. Gut microbiota-dependent trimethylamine-N-oxide and serum biomarkers in patients with T2DM and advanced CKD. J. Clin. Med. 2017; 6(9): 86. DOI: 10.3390/jcm6090086</mixed-citation><mixed-citation xml:lang="en">Al-Obaide M.A.I., Singh R., Datta P., Rewers-Felkins K.A., Salguero M.V., Al-Obaidi I., et al. Gut microbiota-dependent trimethylamine-N-oxide and serum biomarkers in patients with T2DM and advanced CKD. J. Clin. Med. 2017; 6(9): 86. DOI: 10.3390/jcm6090086</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Li J., Lin S., Vanhoutte P.M., Woo C.W., Xu A. Akkermansia muciniphila protects against atherosclerosis by preventing metabolic endotoxemia-induced inﬂammation in Apoe–/– Mice. Circulation. 2016; 133(24): 2434–2446. DOI: 10.1161/CIRCULATIONAHA.115.019645</mixed-citation><mixed-citation xml:lang="en">Li J., Lin S., Vanhoutte P.M., Woo C.W., Xu A. Akkermansia muciniphila protects against atherosclerosis by preventing metabolic endotoxemia-induced inﬂammation in Apoe–/– Mice. Circulation. 2016; 133(24): 24342446. DOI: 10.1161/CIRCULATIONAHA.115.019645</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Лобзин Ю.В., Авдеева М.В., Сидоренко С.В., Лучкевич В.С. Дисбаланс кишечной микробиоты как фактор риска кардиометаболических заболеваний. Журнал инфектологии. 2014; 6(4): 5–12. DOI: 10.22625/2072-6732-2014-6-4-5-12</mixed-citation><mixed-citation xml:lang="en">Lobzin Y.V., Avdeeva M.V., Sidorenko S.V., Luchkevich V.S. Imbalance in the intestinal microbiota as a risk factor of cardiometabolic diseases. Journal Infectology. 2014; 6(4): 5–12 (In Russ., English abstract). DOI: 10.22625/2072-6732-2014-6-4-5-12</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Sun G., Yin Z., Liu N., Bian X., Yu R., Su X., et al. Gut microbial metabolite TMAO contributes to renal dysfunction in a mouse model of diet-induced obesity. Biochem. Biophys. Res. Commun. 2017; 493(2): 964–970. DOI: 10.1016/j.bbrc.2017.09.108</mixed-citation><mixed-citation xml:lang="en">Sun G., Yin Z., Liu N., Bian X., Yu R., Su X., et al. Gut microbial metabolite TMAO contributes to renal dysfunction in a mouse model of diet-induced obesity. Biochem. Biophys. Res. Commun. 2017; 493(2): 964–970. DOI: 10.1016/j.bbrc.2017.09.108</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Chen K., Zheng X., Feng M., Li D., Zhang H. Gut microbiota-dependent metabolite trimethylamine N-oxide contributes to cardiac dysfunction in western diet-induced obese mice. Front. Physiol. 2017; 8: 139. DOI: 10.3389/fphys.2017.00139</mixed-citation><mixed-citation xml:lang="en">Chen K., Zheng X., Feng M., Li D., Zhang H. Gut microbiota-dependent metabolite trimethylamine N-oxide contributes to cardiac dysfunction in western diet-induced obese mice. Front. Physiol. 2017; 8: 139. DOI: 10.3389/fphys.2017.00139</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Ивашкин В.Т., Кашух Е.А. Влияние потребления продуктов, содержащих L-карнитин и фосфатидилхолин, на продукцию проатерогенного метаболита триметиламин-N-оксида и кишечный микробиом у пациентов с ишемической болезнью сердца. Вопросы питания. 2019; 88(4): 25–33. DOI: 10.24411/0042-8833-2019-10038</mixed-citation><mixed-citation xml:lang="en">Ivashkin V.T., Kashukh Ye.A. Impact of L-carnitine and phosphatidylcholine containing products on the proatherogenic metabolite TMAO production and gut microbiome changes in patients with coronary artery disease. Voprosy Pitaniia [Problems of Nutrition]. 2019; 88(4): 25–33 (In Russ., English abstract). DOI: 10.24411/0042-8833-2019-10038</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Boutagy N.E., Neilson A.P., Osterberg K.L., Smithson A.T., Englund T.R., Davy B.M., et al. Probiotic supplementation and trimethylamine-N-oxide production following a high-fat diet. Obesity (Silver Spring). 2015; 23(12): 2357–2363. DOI: 10.1002/oby.21212</mixed-citation><mixed-citation xml:lang="en">Boutagy N.E., Neilson A.P., Osterberg K.L., Smithson A.T., Englund T.R., Davy B.M., et al. Probiotic supplementation and trimethylamine-N-oxide production following a high-fat diet. Obesity (Silver Spring). 2015; 23(12): 2357–2363. DOI: 10.1002/oby.21212</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Malinowska A.M., Szwengiel A., Chmurzynska A. Dietary, anthropometric, and biochemical factors inﬂuencing plasma choline, carnitine, trimethylamine, and trimethylamine-N-oxide concentrations. Int. J. Food Sci. Nutr. 2017; 68(4): 488–495. DOI: 10.1080/09637486.2016.1256379</mixed-citation><mixed-citation xml:lang="en">Malinowska A.M., Szwengiel A., Chmurzynska A. Dietary, anthropometric, and biochemical factors inﬂuencing plasma choline, carnitine, trimethylamine, and trimethylamine-N-oxide concentrations. Int. J. Food Sci. Nutr. 2017; 68(4): 488–495. DOI: 10.1080/09637486.2016.1256379</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Драпкина О.М., Корнеева О.Н. Кишечная микробиота и ожирение. Патогенетические взаимосвязи и пути нормализации кишечной микрофлоры. Терапевтический архив. 2016; 88(9): 135–142. DOI: 10.17116/terarkh2016889135-142</mixed-citation><mixed-citation xml:lang="en">Drapkina O.M., Korneeva O.N. Gut microbiota and obesity: Pathogenetic relationships and ways to normalize the intestinal microﬂora. Terapevticheskii Arkhiv. 2016; 88(9): 135–142 (In Russ., English abstract). DOI: 10.17116/terarkh2016889135-142</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Zeng W., Shen J., Bo T., Peng L., Xu H., Nasser M.I., et al. Cutting edge: Probiotics and fecal microbiota transplantation in immunomodulation. J. Immunol. Res. 2019; 2019: 1603758. DOI: 10.1155/2019/1603758</mixed-citation><mixed-citation xml:lang="en">Zeng W., Shen J., Bo T., Peng L., Xu H., Nasser M.I., et al. Cutting edge: Probiotics and fecal microbiota transplantation in immunomodulation. J. Immunol. Res. 2019; 2019: 1603758. DOI: 10.1155/2019/1603758</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Leshem A., Horesh N., Elinav E. Fecal microbial transplantation and its potential application in cardiometabolic syndrome. Front. Immunol. 2019; 10: 1341. DOI: 10.3389/ﬁmmu.2019.01341</mixed-citation><mixed-citation xml:lang="en">Leshem A., Horesh N., Elinav E. Fecal microbial transplantation and its potential application in cardiometabolic syndrome. Front. Immunol. 2019; 10: 1341. DOI: 10.3389/ﬁmmu.2019.01341</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Sanchez-Rodriguez E., Egea-Zorrilla A., PlazaDíaz J., Aragón-Vela J., Muñoz-Quezada S., TercedorSánchez L., Abadia-Molina F. The gut microbiota and its implication in the development of atherosclerosis and related cardiovascular diseases. Nutrients. 2020; 12(3): 605. DOI: 10.3390/nu12030605</mixed-citation><mixed-citation xml:lang="en">Sanchez-Rodriguez E., Egea-Zorrilla A., Plaza-Díaz J., Aragón-Vela J., Muñoz-Quezada S., Tercedor-Sánchez L., Abadia-Molina F. The gut microbiota and its implication in the development of atherosclerosis and related cardiovascular diseases. Nutrients. 2020; 12(3): 605. DOI: 10.3390/nu12030605</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Ridker P.M., Everett B.M., Thuren T., MacFadyen J.G., Chang W.H, Ballantyne C., et al. CANTOS Trial Group. Antiinﬂammatory therapy with canakinumab for atherosclerotic disease. N. Engl. J. Med. 2017; 377(12): 1119–1131. DOI: 10.1056/NEJMoa1707914</mixed-citation><mixed-citation xml:lang="en">Ridker P.M., Everett B.M., Thuren T., MacFadyen J.G., Chang W.H, Ballantyne C., et al. CANTOS Trial Group. Antiinﬂammatory therapy with canakinumab for atherosclerotic disease. N. Engl. J. Med. 2017; 377(12): 1119–1131. DOI: 10.1056/NEJMoa1707914</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Sugahara H., Odamaki T., Fukuda S., Kato T., Xiao J.Z., Abe F., et al. Probiotic Biﬁdobacterium longum alters gut luminal metabolism through modiﬁcation of the gut microbial community. Sci. Rep. 2015; 5: 13548. DOI: 10.1038/srep13548</mixed-citation><mixed-citation xml:lang="en">Sugahara H., Odamaki T., Fukuda S., Kato T., Xiao J.Z., Abe F., et al. Probiotic Biﬁdobacterium longum alters gut luminal metabolism through modiﬁcation of the gut microbial community. Sci. Rep. 2015; 5: 13548. DOI: 10.1038/srep13548</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
